---
layout: default
title: Pembrolizumab
parent: Model Prediction Only (L5)
nav_order: 711
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Pembrolizumab: From Cancer Immunotherapy (e.g., Non-Small-Cell Lung Cancer) to Gingival Fibromatosis

## One-Sentence Summary

Pembrolizumab is a PD-1 checkpoint-inhibitor antibody used in cancer treatment, including non-small-cell lung cancer (NSCLC).
The TxGNN model predicts it may be effective for **gingival fibromatosis** with a very high score (99.4%), but **0 clinical trials** and **0 publications** support this prediction.
This is a model-only prediction and is most likely a knowledge-graph artifact.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Cancer immunotherapy (e.g., non-small-cell lung cancer) |
| Predicted New Indication | Gingival fibromatosis |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the Evidence Pack. Based on the literature retrieved for other predictions, pembrolizumab is a humanized IgG4-kappa monoclonal antibody against PD-1. It blocks the PD-1/PD-L1 interaction, which restores T-cell activity against tumour cells that evade the immune system.

This mechanism does not transfer well to gingival fibromatosis. The condition is a non-malignant fibrotic overgrowth of the gums, usually genetic or drug-induced. No PD-1/PD-L1 rationale for it was identified. Pembrolizumab's immune-related adverse event profile also argues against using it in a benign condition.

The high TxGNN score is therefore best read as a graph-proximity effect, not as a credible pharmacological signal. It should not be treated as a repurposing lead without independent supporting evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2456869 | KEYTRUDA |

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (PD-1 immune checkpoint inhibitor, monoclonal antibody) |
| Myelosuppression Risk | Low (not a conventional cytotoxic agent). Please refer to the package insert for details. |
| Emetogenicity Classification | Low |
| Monitoring Items | Thyroid, liver and renal function, blood glucose, and clinical monitoring for immune-related adverse events; CBC as clinically indicated |
| Handling Protection | Not a conventional cytotoxic agent. Please refer to the package insert and local institutional policy for handling requirements. |

---

## Safety Considerations

Pembrolizumab can cause immune-related adverse events, which weighs against its use in a benign condition such as gingival fibromatosis.

Please refer to the package insert for full safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the model score, with no trials, no literature and no plausible PD-1 mechanism for a benign fibrotic gingival condition. The risk-benefit balance is unfavourable.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications
- Mechanism-of-action data from DrugBank
- Any disease-specific preclinical or clinical evidence linking PD-1 blockade to gingival fibromatosis
- Review of the other predicted indications. Lung hilum carcinoma and pulmonary sulcus neoplasm are likely better handled by re-mapping to the existing NSCLC evidence, not as new repurposing candidates.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

